GenSci Invites you to join us in CPHI South East Asia 2024

Jul. 04, 2024, Shanghai - GenSci, a leading innovator in the pharmaceutical industry, is pleased to announce our participation in the CPHI South East Asia 2024 exhibition, taking place in Bangkok, Thailand. We invite you to visit us at Booth H23 from July 10 to 12, 2024, where we will share our latest innovations and flagship products.

At this exhibition，GenSci will showcase our product portfolio including Jintrolong® PEG-SOMATROPIN, Jintropin® AQ SOMATROPIN INJECTION, Jinfollin® FOLLITROPIN and Genfulin® MOLGRAMOSTIM GEL, etc. Cordially welcome professionals and partners to visit our booth and explore collaboration opportunities.

As a pioneering genetic engineering pharmaceutical company, GenSci is committed to enhancing the well-being of women and children. Leveraging decades of expertise in biopharmaceuticals and drug innovation, our company is broadening its horizons to encompass a diverse array of therapeutic are, such as Endocrinology, Immunology, and Oncology. In response to the global demand for innovative healthcare solutions, GenSci has strategically positioned itself in pivotal markets, including North America and Europe. 

Our commitment to global health is further exemplified by the establishment of our branch in Singapore, from which we aim to penetrate the burgeoning Southeast Asian market. Our mission is to deliver cutting-edge healthcare solutions to patients in this dynamic region.

The CPHI South East Asia conference stands as a pivotal event in the ASEAN pharmaceutical industry, serving as a platform for the most significant industry gatherings. We are eager to connect with the vibrant pharmaceutical community in this esteemed conference, fostering collaboration and propelling forward the frontiers of pharmaceutical innovation.